image

Immunology Market Report Scope And Overview:

The Immunology Market is estimated to be valued at US$ 91,851 Million in 2022 and is expected to reach US$ 156,378.3 million by 2030, at a CAGR of 9% during the forecast period (2023–2030).

The study of autoimmune diseases, in which the body's immune system targets a component of its own tissues as though it were a foreign object, is another area of growing importance within the field of immunology. The market demand for Immunology Market drugs is rising primarily because of the rising awareness of Immunology Market diseases in both developed and developing countries, as well as the rising prevalence of Immunology Market disorders caused by environmental factors. The aim of the worldwide immunology market is to tackle diverse immune-related ailments and conditions through the creation of novel treatments and diagnostic instruments.

The future competitive dynamics in immunology and the evolving landscape of innovation are being shaped by two major trends. Biologic therapies, which have demonstrated high efficacy and safety, are the mainstay of immunology. While some of these therapies are still administered as infusions, most require injections. Therefore, innovators aim to balance the convenience of a pill, or to a lesser extent a topical formulation, with superior, biologic-like efficacy and safety. Precision medicine: In their respective clinical trials, Merck/Prometheus' PRA023 and Roivant's RVT-3101, two TL1A inhibitor assets currently being studied in ulcerative colitis and Crohn's disease, are using (yet-to-be-disclosed) biomarkers for patient stratification.

Market Dynamics

Drivers

  • Immunology Market Growth is Anticipated to Be Boosted by Growing Novel Therapies and Rising Prevalence of Autoimmune Disorders

Numerous factors, including infections, stress, certain foods, gut dysbiosis, and exposure to dangerous substances, account for a significant percentage of people with autoimmune illnesses. Autoimmune diseases are the third most common chronic condition in the United States, affecting about 50 million people at any given time. For example, a National Stem Cell Foundation study found that approximately 4% of people worldwide suffer from at least one of the 80 or more autoimmune illnesses.

Due to the increasing patient demand for these drugs, industry players are putting in a lot of effort into creating and releasing new products. As a result, the pipeline portfolios of the leading players in the immunology market are growing quickly.

Restraint

  • Increased Treatment Costs and Unfavorable Product Side Effects Are Anticipated to Limit Immunology Market Growth

The high cost of treatments and their unfavorable side effects will limit the market's growth during the projected period, even though Immunology Market illnesses are becoming more common in important countries. Because of the high cost of manufacturing facilities and the substantial research and development needed to get biologics through FDA clearance and clinical trial procedures, biopharmaceuticals are particularly expensive.

Consequently, the aforementioned factor and the stringent compensation laws in developing countries impeded market expansion during the research period.

Opportunities

  • Rising demand for Hospital, Retail & Online Pharmacies

In the upcoming years, the "Immunology Market" is anticipated to grow significantly, mostly due to the rising demand for (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), The market can be divided into categories according to the Drug class, which include prophylaxis of organ rejection, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, and inflammatory bowel disease.

Challenges

  • Lack of knowledge about immunology

One of the biggest obstacles to the global immunology market's expansion is a lack of knowledge about immunology. The development of the worldwide immunology market will be negatively impacted by a lack of knowledge about immune-mediated cancers since it will restrict the use of medications. Achieving true marketability of available products is challenging due to awareness issues. One of the more prevalent health issues affecting people's everyday lives is allergies. Due to a lack of knowledge, allergies are still underdiagnosed and undertreated despite their high prevalence.

Furthermore, a notable deficiency in knowledge exists regarding the significance of fatigue as a symptom of rheumatoid arthritis. Additionally, according to the NIH, over one-third of patients with symptoms of asthma and rhinitis go undiagnosed, which lowers their quality of life. Even though there are effective treatments available, poor treatment adherence is often caused by personal attitudes, beliefs, and a lack of communication between the patient and the clinician, particularly in chronic conditions like allergies and asthma. Therefore, during the forecast period, the global immunology market is likely to face significant challenges due to a lack of awareness.

Impact of ongoing Recession

Globally, almost every sector has been impacted by the global economic crisis, which is regarded as one of the worst since the Great Depression of 1930. The US mortgage market, which sold subprime mortgages to a large number of people with low incomes, is the primary cause of the current economic and financial crisis. A developed country's integration of the global economic crisis has a long-lasting effect on developing and third-world nations like India. India, a developing country, is also dealing with the difficulties brought on by this crisis. Since it has impacted every industry, the health care sector is not exempt from this monster. Due to its very nature of providing necessary and inescapable services, the health sector is thought to be immune to the global crisis; however, some aspects of the health care domain have been slightly impacted.

IMPACT OF RUSSIAN UKRAINE WAR

Russia started encroaching on Ukraine militarily. The Russian invaders' tactics and strategy now include targeting healthcare facilities.

Even during times of peace, the Ukrainian healthcare system was far from perfect. The supply of medications for people with chronic illnesses was frequently interrupted, physicians bemoaned their meager pay, and hospital extortions were no longer shocking. The war had every opportunity to destroy the system entirely, but instead it forced the authorities and regional experts to come up with workable solutions, which is how the nation's medical field not only survived but also kept evolving. 

The war uncovered flaws in every aspect of government, including the medical field. The fact that medical facilities do not have complete bomb shelters was one of the most painful lessons learned. Rather conceitedly named shelters, the cellars were frequently converted into mass graves during periods of intense shelling. Even for healthy individuals, they are unsuitable as a shelter due to the absence of a solid ceiling, an independent ventilation system, and a water supply. The lengthy hospital stays of patients who require therapy for severe illnesses don't need to be discussed.

KEY SEGMENTS

By Drug Class

  • Monoclonal Antibody (mAb)

  • Fusion Proteins

  • Immunosuppressants

  • Polyclonal Antibody (pAb)

By Disease Indication 

  • Rheumatoid Arthritis,

  • Psoriatic Arthritis

  • Plaque Psoriasis

  • Ankylosing Spondylitis

  • Inflammatory Bowel Disease

  • Prophylaxis of Organ Rejection

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

REGIONAL COVERAGE:

 

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Netherlands

  • Switzerland

  • Austria

  • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

Regional Analysis

North America's established healthcare infrastructure is expected to contribute to its dominance of the immunology market share. With a market value of USD 54.04 billion in 2021, North America is poised to capture a sizable chunk of the global market share in the years to come. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the industry.

The rising incidence of autoimmune diseases in Europe is probably going to help drive up demand for immunology medications. This element is anticipated to accelerate market development in the area.

It is anticipated that the growing number of people in Asia Pacific with various autoimmune diseases will increase demand for immunology services. Moreover, the market is anticipated to be stimulated by the growing approvals and launch initiatives by major players.

Key Players

Some of the major players of Immunology Market are Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc. and other key players.

Recent Development

December 2021- In the US, Amgen Inc.'s Otezla immunology drug was approved by the FDA. Adult plaque is the target market for this product.

March 2022- Pfizer Inc. expanded its range of products through the acquisition of Arena Pharmaceuticals, a business focused on creating innovative treatments for a range of inflammatory immune disorders.

Immunology Market Report Scope:

Report Attributes Details
Market Size in 2022  US$ 91,851 Million
Market Size by 2030  US$ 156,378.3 Million
CAGR   CAGR of 9 % From 2023 to 2030
Base Year 2022
Forecast Period  2023-2030
Historical Data  2019-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Drug Class (Monoclonal Antibody (MAb), Fusion Proteins, Immunosuppressant, Polyclonal Antibody (PAb))
• By Disease Indicator(Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis Of Organ Rejection)
• By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc.
Key Drivers • Immunology Market Growth is Anticipated to Be Boosted by Growing Novel Therapies and Rising Prevalence of Autoimmune Disorders
Market Restraint • Increased Treatment Costs and Unfavorable Product Side Effects Are Anticipated to Limit Immunology Market Growth

 

Frequently Asked Questions

The Compound Annual Growth rate for the immunology market over the forecast period is 9%.

The projected market size for the immunology market is USD 156,378.3 million by 2030. 

The high cost of treatments and their unfavorable side effects.

Immunology market growth is anticipated by growing novel therapies and rising prevalence of autoimmune disorders.

North America dominated the global market in 2022.

TABLE OF CONTENTS

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Industry Flowchart

3. Research Methodology

4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges

5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India

6. Value Chain Analysis

7. Porter’s 5 Forces Model

8.  Pest Analysis

9. Immunology Market, By Drug class
9.1 Introduction
9.2 Trend Analysis
9.3 Monoclonal Antibody (mAb)
9.4 Fusion Proteins
9.5 Immunosuppressant
9.6 Polyclonal Antibody (pAb)

10. Immunology Market, By Disease indicator
10.1 Introduction
10.2 Trend Analysis
10.3 Rheumatoid Arthritis
10.4 Psoriatic Arthritis
10.5 Plaque Psoriasis
10.6 Ankylosing Spondylitis
10.7 inflammatory Bowel Disease
10.8 Prophylaxis of Organ Rejection

11. Immunology Market, By Distribution channel
11.1 Introduction
11.2 Trend Analysis
11.3 Hospital pharmacies
11.4 Retail pharmacies
11.5 Online pharmacies

12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 Trend Analysis
12.2.2 North America Immunology Market by Country
12.2.3 North America Immunology Market By Drug class
12.2.4 North America Immunology Market By Disease indicator
12.2.5 North America Immunology Market By Distribution channel
12.2.6 USA
12.2.6.1 USA Immunology Market By Drug class
12.2.6.2 USA Immunology Market By Disease indicator
12.2.6.3 USA Immunology Market By Distribution channel
12.2.7 Canada
12.2.7.1 Canada Immunology Market By Drug class
12.2.7.2 Canada Immunology Market By Disease indicator
12.2.7.3 Canada Immunology Market By Distribution channel
12.2.8 Mexico
12.2.8.1 Mexico Immunology Market By Drug class
12.2.8.2 Mexico Immunology Market By Disease indicator
12.2.8.3 Mexico Immunology Market By Distribution channel
12.3 Europe
12.3.1 Trend Analysis
12.3.2 Eastern Europe
12.3.2.1 Eastern Europe Immunology Market by Country
12.3.2.2 Eastern Europe Immunology Market By Drug class
12.3.2.3 Eastern Europe Immunology Market By Disease indicator
12.3.2.4 Eastern Europe Immunology Market By Distribution channel
12.3.2.5 Poland
12.3.2.5.1 Poland Immunology Market By Drug class
12.3.2.5.2 Poland Immunology Market By Disease indicator
12.3.2.5.3 Poland Immunology Market By Distribution channel
12.3.2.6 Romania
12.3.2.6.1 Romania Immunology Market By Drug class
12.3.2.6.2 Romania Immunology Market By Disease indicator
12.3.2.6.4 Romania Immunology Market By Distribution channel
12.3.2.7 Hungary
12.3.2.7.1 Hungary Immunology Market By Drug class
12.3.2.7.2 Hungary Immunology Market By Disease indicator
12.3.2.7.3 Hungary Immunology Market By Distribution channel
12.3.2.8 Turkey
12.3.2.8.1 Turkey Immunology Market By Drug class
12.3.2.8.2 Turkey Immunology Market By Disease indicator
12.3.2.8.3 Turkey Immunology Market By Distribution channel
12.3.2.9 Rest of Eastern Europe
12.3.2.9.1 Rest of Eastern Europe Immunology Market By Drug class
12.3.2.9.2 Rest of Eastern Europe Immunology Market By Disease indicator
12.3.2.9.3 Rest of Eastern Europe Immunology Market By Distribution channel
12.3.3 Western Europe
12.3.3.1 Western Europe Immunology Market by Country
12.3.3.2 Western Europe Immunology Market By Drug class
12.3.3.3 Western Europe Immunology Market By Disease indicator
12.3.3.4 Western Europe Immunology Market By Distribution channel
12.3.3.5 Germany
12.3.3.5.1 Germany Immunology Market By Drug class
12.3.3.5.2 Germany Immunology Market By Disease indicator
12.3.3.5.3 Germany Immunology Market By Distribution channel
12.3.3.6 France
12.3.3.6.1 France Immunology Market By Drug class
12.3.3.6.2 France Immunology Market By Disease indicator
12.3.3.6.3 France Immunology Market By Distribution channel
12.3.3.7 UK
12.3.3.7.1 UK Immunology Market By Drug class
12.3.3.7.2 UK Immunology Market By Disease indicator
12.3.3.7.3 UK Immunology Market By Distribution channel
12.3.3.8 Italy
12.3.3.8.1 Italy Immunology Market By Drug class
12.3.3.8.2 Italy Immunology Market By Disease indicator
12.3.3.8.3 Italy Immunology Market By Distribution channel
12.3.3.9 Spain
12.3.3.9.1 Spain Immunology Market By Drug class
12.3.3.9.2 Spain Immunology Market By Disease indicator
12.3.3.9.3 Spain Immunology Market By Distribution channel
12.3.3.10 Netherlands
12.3.3.10.1 Netherlands Immunology Market By Drug class
12.3.3.10.2 Netherlands Immunology Market By Disease indicator
12.3.3.10.3 Netherlands Immunology Market By Distribution channel
12.3.3.11 Switzerland
12.3.3.11.1 Switzerland Immunology Market By Drug class
12.3.3.11.2 Switzerland Immunology Market By Disease indicator
12.3.3.11.3 Switzerland Immunology Market By Distribution channel
12.3.3.1.12 Austria
12.3.3.12.1 Austria Immunology Market By Drug class
12.3.3.12.2 Austria Immunology Market By Disease indicator
12.3.3.12.3 Austria Immunology Market By Distribution channel
12.3.3.13 Rest of Western Europe
12.3.3.13.1 Rest of Western Europe Immunology Market By Drug class
12.3.3.13.2 Rest of Western Europe Immunology Market By Disease indicator
12.3.3.13.3 Rest of Western Europe Immunology Market By Distribution channel
12.4 Asia-Pacific
12.4.1 Trend Analysis
12.4.2 Asia-Pacific Immunology Market by Country
12.4.3 Asia-Pacific Immunology Market By Drug class
12.4.4 Asia-Pacific Immunology Market By Disease indicator
12.4.5 Asia-Pacific Immunology Market By Distribution channel
12.4.6 China
12.4.6.1 China Immunology Market By Drug class
12.4.6.2 China Immunology Market By Disease indicator
12.4.6.3 China Immunology Market By Distribution channel
12.4.7 India
12.4.7.1 India Immunology Market By Drug class
12.4.7.2 India Immunology Market By Disease indicator
12.4.7.3 India Immunology Market By Distribution channel
12.4.8 Japan
12.4.8.1 Japan Immunology Market By Drug class
12.4.8.2 Japan Immunology Market By Disease indicator
12.4.8.3 Japan Immunology Market By Distribution channel
12.4.9 South Korea
12.4.9.1 South Korea Immunology Market By Drug class
12.4.9.2 South Korea Immunology Market By Disease indicator
12.4.9.3 South Korea Immunology Market By Distribution channel
12.4.10 Vietnam
12.4.10.1 Vietnam Immunology Market By Drug class
12.4.10.2 Vietnam Immunology Market By Disease indicator
12.4.10.3 Vietnam Immunology Market By Distribution channel
12.4.11 Singapore
12.4.11.1 Singapore Immunology Market By Drug class
12.4.11.2 Singapore Immunology Market By Disease indicator
12.4.11.3 Singapore Immunology Market By Distribution channel
12.4.12 Australia
12.4.12.1 Australia Immunology Market By Drug class
12.4.12.2 Australia Immunology Market By Disease indicator
12.4.12.3 Australia Immunology Market By Distribution channel
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Immunology Market By Drug class
12.4.13.2 Rest of Asia-Pacific Immunology Market By Disease indicator
12.4.13.3 Rest of Asia-Pacific Immunology Market By Distribution channel
12.5 Middle East & Africa
12.5.1 Trend Analysis
12.5.2 Middle East
12.5.2.1 Middle East Immunology Market by Country
12.5.2.2 Middle East Immunology Market By Drug class
12.5.2.3 Middle East Immunology Market By Disease indicator
12.5.2.4 Middle East Immunology Market By Distribution channel
12.5.2.5 UAE
12.5.2.5.1 UAE Immunology Market By Drug class
12.5.2.5.2 UAE Immunology Market By Disease indicator
12.5.2.5.3 UAE Immunology Market By Distribution channel
12.5.2.6 Egypt
12.5.2.6.1 Egypt Immunology Market By Drug class
12.5.2.6.2 Egypt Immunology Market By Disease indicator
12.5.2.6.3 Egypt Immunology Market By Distribution channel
12.5.2.7 Saudi Arabia
12.5.2.7.1 Saudi Arabia Immunology Market By Drug class
12.5.2.7.2 Saudi Arabia Immunology Market By Disease indicator
12.5.2.7.3 Saudi Arabia Immunology Market By Distribution channel
12.5.2.8 Qatar
12.5.2.8.1 Qatar Immunology Market By Drug class
12.5.2.8.2 Qatar Immunology Market By Disease indicator
12.5.2.8.3 Qatar Immunology Market By Distribution channel
12.5.2.9 Rest of Middle East
12.5.2.9.1 Rest of Middle East Immunology Market By Drug class
12.5.2.9.2 Rest of Middle East Immunology Market By Disease indicator
12.5.2.9.3 Rest of Middle East Immunology Market By Distribution channel
12.5.3 Africa
12.5.3.1 Africa Immunology Market by Country
12.5.3.2 Africa Immunology Market By Drug class
12.5.3.3 Africa Immunology Market By Disease indicator
12.5.3.4 Africa Immunology Market By Distribution channel
12.5.3.5 Nigeria
12.5.3.5.1 Nigeria Immunology Market By Drug class
12.5.3.5.2 Nigeria Immunology Market By Disease indicator
12.5.3.5.3 Nigeria Immunology Market By Distribution channel
12.5.3.6 South Africa
12.5.3.6.1 South Africa Immunology Market By Drug class
12.5.3.6.2 South Africa Immunology Market By Disease indicator
12.5.3.6.3 South Africa Immunology Market By Distribution channel
12.5.3.7 Rest of Africa
12.5.3.7.1 Rest of Africa Immunology Market By Drug class
12.5.3.7.2 Rest of Africa Immunology Market By Disease indicator
12.5.3.7.3 Rest of Africa Immunology Market By Distribution channel
12.6 Latin America
12.6.1 Trend Analysis
12.6.2 Latin America Immunology Market by country
12.6.3 Latin America Immunology Market By Drug class
12.6.4 Latin America Immunology Market By Disease indicator
12.6.5 Latin America Immunology Market By Distribution channel
12.6.6 Brazil
12.6.6.1 Brazil Immunology Market By Drug class
12.6.6.2 Brazil Immunology Market By Disease indicator
12.6.6.3 Brazil Immunology Market By Distribution channel
12.6.7 Argentina
12.6.7.1 Argentina Immunology Market By Drug class
12.6.7.2 Argentina Immunology Market By Disease indicator
12.6.7.3 Argentina Immunology Market By Distribution channel
12.6.8 Colombia
12.6.8.1 Colombia Immunology Market By Drug class
12.6.8.2 Colombia Immunology Market By Disease indicator
12.6.8.3 Colombia Immunology Market By Distribution channel
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Immunology Market By Drug class
12.6.9.2 Rest of Latin America Immunology Market By Disease indicator
12.6.9.3 Rest of Latin America Immunology Market By Distribution channel

13 Company profile
13.1 UCB SA
13.1.1 Market Overview
13.1.2 Financials
13.1.3 Treatment/End-User/Offerings
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 AbbVie Inc.
13.2.1 Market Overview
13.2.2 Financials
13.2.3 Treatment/End-User/Offerings
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 F. Hoffmann-La Roche Ltd
13.3.1 Market Overview
13.3.2 Financials
13.3.3 Treatment/End-User/Offerings
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Astellas
13.4.1 Market Overview
13.4.2 Financials
13.4.3 Treatment/End-User/Offerings
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Pfizer Inc.
13.5.1 Market Overview
13.5.2 Financials
13.5.3 Treatment/End-User/Offerings
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Amgen Inc.
13.6.1 Market Overview
13.6.2 Financials
13.6.3 Treatment/End-User/Offerings
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 ALLERGAN
13.7.1 Market Overview
13.7.2 Financials
13.7.3 Treatment/End-User/Offerings
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Novartis AG
13.8.2 Financials
13.8.3 Treatment/End-User/Offerings
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Bristol-Myers Squibb Company
13.9.1 Market Overview
13.9.2 Financials
13.9.3 Treatment/End-User/Offerings
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Janssen Global Services, LLC (Johnson & Johnson)
13.10.1 Market Overview
13.10.2 Financials
13.10.3 Treatment/End-User/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View

14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions

15. Use Case and Best Practices

16. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone